Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

I think they used to call this Candyflipping…ok not exactly but you know what I’m driving at. Sort of thing they used to bang you up in the states for 300 years for being a menace to society.

The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders

Vancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication in the United States of three patent applications covering novel proprietary combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, such as palmitoylethanolamide (“PEA”). The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression, post-traumatic stress disorder (“PTSD”), pain and substance use disorders.

The publications expand the intellectual property generated through Clearmind’s ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX), under which NeuroThera’s PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. The collaboration has resulted in a growing portfolio of patent applications covering combinations of PEA with psychedelic and psychoactive compounds. Clearmind previously announced U.S. publication of a patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

“The publication of these patents come at a significant time as clinical and regulatory interest in LSD, ketamine and ibogaine continues to receive growing recognition and support for their therapeutic potential. Clearmind believes its combination approach may offer the potential for an effective and safer treatment paradigm, aiming to achieve therapeutic benefits at lower doses while preserving efficacy. By reducing the dose required to achieve the intended pharmacological effect, this approach may support improved tolerability while maintaining therapeutic potential.,” said Adi Zuloff‑Shani, Ph.D., Chief Executive Officer of Clearmind.